CA1332495C - In situ calcium phosphate minerals -- method and composition - Google Patents

In situ calcium phosphate minerals -- method and composition

Info

Publication number
CA1332495C
CA1332495C CA000597140A CA597140A CA1332495C CA 1332495 C CA1332495 C CA 1332495C CA 000597140 A CA000597140 A CA 000597140A CA 597140 A CA597140 A CA 597140A CA 1332495 C CA1332495 C CA 1332495C
Authority
CA
Canada
Prior art keywords
calcium
mixture
hydroxyapatite
source
calcium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000597140A
Other languages
French (fr)
Inventor
Brent R. Constantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norian Corp
Original Assignee
Norian Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22674214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1332495(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Norian Corp filed Critical Norian Corp
Application granted granted Critical
Publication of CA1332495C publication Critical patent/CA1332495C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/30Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/50Preparations specially adapted for dental root treatment
    • A61K6/54Filling; Sealing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/70Preparations for dentistry comprising inorganic additives
    • A61K6/71Fillers
    • A61K6/74Fillers comprising phosphorus-containing compounds
    • A61K6/75Apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/831Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
    • A61K6/838Phosphorus compounds, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/864Phosphate cements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/873Carbonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/876Calcium oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/32Phosphates of magnesium, calcium, strontium, or barium
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/32Phosphates of magnesium, calcium, strontium, or barium
    • C01B25/322Preparation by neutralisation of orthophosphoric acid
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/32Phosphates of magnesium, calcium, strontium, or barium
    • C01B25/327After-treatment
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00Phosphorus; Compounds thereof
    • C01B25/16Oxyacids of phosphorus; Salts thereof
    • C01B25/26Phosphates
    • C01B25/455Phosphates containing halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • A61F2002/2817Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30062(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00179Ceramics or ceramic-like structures
    • A61F2310/00293Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/901Method of manufacturing prosthetic device

Abstract

Calcium phosphate minerals are formed by using phosphoric acid substantially free of uncombined water in conjunction with a calcium source, normally as any combination of carbonate, phosphate and hydroxide, and, as required, any additional base to neutralize the phosphoric acid. Protein may be optionally added. The resulting product is readily formed and then sets to a hard, stable, workable shaped object.

Description

1332~95 IN SIT~ CALCIUM PHOSPHATE MINERALS
----METHOD AND COMPOSITION

The invention concerns the preparation of calcium phosphate minerals and their applications.

A number of calcium phosphate minerals, such as hydroxyapatite, fluorapatite, octacalcium phosphate (OCP), whitlockite ~B-TCP), brushite and monetite, do, or may, find application as biocompatible minerals.
20 The various crystalline forms have different properties which in particular applications may be more or less desirable. For example, OCP (kSp Y 10 27), TCP ( or B
form) or Ca3_yMgx(PO4)2 (kSp Y 10-27) are resorbable, while brushite (CaHPO4-2H2O) (kSp Y 10 7) and monetite 25 (CaHPO4) (kSp Y 10-7) are very resorbable. (Brown and Chow, Ann. Rev. of Materials Science (1976) 6:213-236). By forming the different minerals with their varying crystalline structures, compositions and chemical and physical properties, mineral products may 30 be obtained having different properties for particular applications .
Apatite is a general term for a wide range of compounds represented by the general formula M2+1o(Zo43 )6Y 2' wherein M is a metal atom, partic-35 ularly alkali or alkaline earth metal atom, and ZO4 isan acid radical, where Z may be phosphorus, arsenic, vanadium, sulfur or silicon, or may be substituted in whole or in part with carbonate (C032-). Y is an 1332A~

anion, usually halide, hydroxy, or carbonate.
Elydroxyapatite, as well as modified forms thereof, assumes substantial interest and importance by 5 virtue of the fact that it is a major naturally occurring building block in bone, teeth, and some invertebrate skeletons. There are many situations where bone has been broken, destroyed, degraded, become too brittle, or been subject to other deteriorating 10 effects. In many of these situations it would be desirable to be able to replace the bone structure or strengthen the bone structure. In providing materials to substitute for natural bone, there are a number of restraints on the nature and composition of the 15 material.
The material should be physiologically acceptable, so as to avoid the initiation of clots, inflammatory response, and the like. Two different product forms are desirable: One being an hydroxy- or 20 fluorapatite which is non-resorbable in vivo; the other including substantial amounts of carbonated apatite, calcium deficient apatite, OCP, TCP, brushite, and monetite, which are resorbable in vivo. In addition, the material must be strong and not friable.
25 Furthermore, there should be strong adhesion between the material and any remaining bone. Also, desirably, the material should be subject to assuming some of the natural role of bone, such as accommodating stem cells, allowing remodelling by osteoclasts followed by new 30 bone ingrowth, and normal metabolic calcium exchange of native bone .
sesides the biological and physiological considerations, there are the additional considerations of how the material is made and the ease with which it 35 may be formed to a desired shape. Specifically, a material which could be injected as a liquid to fill voids and completely fill in areas deficient of hard bone is very desirable. Where the material is to be 3 1332~9~
placed in situ, a variety of considerations come to the fore. For example, t-he rate at which the reaction occurs for formation of hydroxyapatite, as well as the 5 change in enthalpy of the reaction, are important.
Where the reaction is highIy exothermic, it may not be tolerated by the patient. The form in which it is introduced must be stable in the environment in which it is introduced, so that not only must the final 10 product be stable, but also the intermediate products as the reaction occurs.
It has therefore been found difficult to provide physiologically useful forms of hydroxyapatite and/or other calcium phosphate minerals. For the most 15 part, the hydroxyapatites and other calcium phosphate bone grafting particulates which have been available have lacked one or more of the properties necessary for a useful implant, and, therefore, have failed to obtain general acceptance.

Relevant Literature Patents of interest include U . S . Patent Nos. 3,787,900; 3,913,229; 3,679,360; 4,097,935;
4,481,175; 4,503,157; 4,612,053; 4,659,617; and 4,693,986. See also, Arends and Jongebloed, Rec. Trav.
Chim. Pays-Bas (1981) 100:3-9. Use of calcium phosphate as a sealer-filler material is described in Chohayeb et al., J. ~ndodontics (1987) 13:384_387. See also Ohwaki et al. 13th Ann. Mtg. of the Soc. for _ _ , Biomaterials, June 2-6, 1987, New York, NY, p. 209.
This invention provides a method for making calcium phosphate minerals comprising:
combining phosphoric acid substantially free of uncombined water, a calcium source, neutralizing anions including at least one of carbonate, phosphate and hydroxide in an amount suf f icient to substantially 3a 1332~9~
neutralize said phosphoric acid and water in an amount to provide a kneadable mixture;
agitating the mixture to produce a substantially uniform mixture; and allowing the uniform mixture to set and become annealed to a hard workable structure.
This invention also provides a method for making hydroxyapatite comprising:
combining orthophosphoric acid crystals, a neutralizing source comprising at least one of calcium carbonate, alkali metal hydroxide, calcium hydroxide and calcium phosphate, in an amount sufficient to provide a substantially neutral product, and water in an amount to provide a kneadable mixture;
agitating the mixture to produce a substantially uniform mixture; and allowing the uniform mixture to set and become matured to a hard workable structure.
This invention also provides calcium phosphate 2 0 and hydroxyapatite prepared according to the preceding methods, as well as formed objects of calcium phosphate and hydroxyapatite.
Calcium phosphate minerals are prepared using highly concentrated phosphoric acid as a liquid or solid, substantially free of uncombined water, a source of an alkaline earth metal, particularly calcium, usually at least in part basic, optionally a base 4 1332~9~
source other than a basic calcium source, a lubricant, such as water, and optionally hydroxyapatite crystals. The components are thoroughly mixed to 5 provide a substantially uniform mixture, at which time the product may be shaped, followed by standing to form a solid mass and hardening to a final stable form.
Ceramic fibers, proteins and/or organic polymers may be added to this product during mixing to give the final 10 product specific material properties.
Methods and compositions are provided for 15 producing bone-like materials comprising structures analogous to the naturally occurring calcium phosphate minerals, particularly carbonated, fluoro- and hydroxyapatite. The products are readily formed by combining the reactants to provide a substantially 20 uniform mixture, shaping the mixture as appropriate, and allowing the mixture to form a solid mass and harden. The reactants are for the most part a phosphoric acid source, substantially free of unbound water, an alkaline earth metal, particularly calcium, 25 source, optionally crystalline nuclei, particularly calcium phosphate crystals, more particularly hydroxyapatite crystals, optionally, a source of base other than a basic calcium compound such as a calcium phosphate, particularly a calcium hydroxide, oxide 30 and/or carbonate, and a lubricant such as water. The dry ingredients may be pre-prepared as a mixture and combined with the liquid ingredients, under conditions where substantially uniform mixing occurs. Where gases evolve, the mixture is agitated, so as to provide for 35 the release of any large pockets of gas. After a short mixing time period, the mixture is allowed to anneal while remaining quiescent, followed by an extended period of time of hardening.

s 1332~95 By employing the subject procedures, compositions are obtained which have a wide variety of desirable properties for use in physiological purposes. The subject compositions are biocompatible having a pH in the range of about 5-8, usually in the range of about 6-7.5. They can be prepared, so that they can be administered at a temperature in the range of about 0-45C, usually 20-40C, and optimally about normal physiological temperature, 37C. The composition has low or no toxicity when prepared in accordance with the subject invention, is substantially inactive, so far as detrimental interactions with various host components in vivo, and readily implantable. The implantation may be as a result of syringe or catheter injection, particularly the composition may be used as a paste which passes through a needle in the range of 10-18 gauge, preferably about 14-16 gauge. Alternatively, the composition is moldable, being capable of forming a clay-like putty which may be molded prior to setting.
The subject compositions also bond to other calcium phosphates when applied to a calcium phosphate surface, such as bones and teeth which are mainly hydroxyapatite and collagen. The composition is able to bond to surfaces which are wet or coated with blood, will fill voids, conforming with irregular surfaces, such as concavities and convexities. The composition may be applied as a continuous mass without the forma-tion of fragments or loose particles to any significant degree. Furthermore, the subject compositions are found to be structurally compatible in providing for the structural functions of the replaced connective tissue .
The subject compositions may also be used as a delivery system, since the resorption rate in vivo may be varied by varying the mineralogy of the crystallized calcium phosphate minerals. In this manner, the 6 1332~95 subject compositions may provide for a wide range of rate of release of compounds having physiological properties. Compounds of interest may include various 5 factors, such as bone morphogenic proteins, which may provide the implant similar inductive potential to a natural allograft or autograft of bone. Alternatively, various drugs may be employed in the composition, which may serve to prevent infection, attract blood cells, 10 activate cells, and the like. The compositions may be modified by employing various natural or synthetic proteins, particularly polypeptides such as collagen, chitin, fibrin, heparin, etc. Alternatively, various materials may be included which may provide for x-ray lS opacity. For example, 10-30% by weight of bismuth oxide, barium sulfate, barium carbonate or zirconium oxide may be incorporated in the composition. For magnetic resonance imaging, various elemental isotopes may be employed for the composition, such as 19F, 31p, 180, and 41Ca.
By the materials employed and their propor-tions, the compositions, during formation, handling, and as the final product may be varied widely as to their physical properties. The composition may be prepared at various degrees of fluidity, such as flowability or viscosity, by varying the amounts of lubricant employed, particularly water, or other hydroxylic compound, e.g., ethylene or polyethylene glycol. 8y using less liquid, or by the choice of other materials, the composition may be made less flowable and more formable, providing a consistency of modeling clay, so that the composition may be formed into a desired form.
The mechanical and physical properties of the final product may be varied widely. For example, the bulk porosity may be varied, depending on the particular ions which are used in the formation of the product. Also, microstructure may be varied, since the 7 1332~9~
shapes and the size of the crystals can be varied with resulting variation in the mechanical properties of the product. Another parameter of interest is bulk 5 permeability, since the permeability may be changed in relation to the particular application where a permeable or impermeable product may be desired. Also, the surface area may be varied, where a high surface area may be desirable, for example, greater than 10 lOm2/gm, to enhance protein bonding, particularly charged proteins.
The individual components in the reaction preparing the subject compositions will now be considered .
The phosphoric acid source may be varied.
Depending upon the phosphoric acid source, the reaction may be exothermic, endothermic, or result in substan-tially no change in temperature of the mixture. A
phosphoric acid source, greater than about 85%
20 phosphoric acid, liquid or solid, amorphous or crystalline, should be substantially free of unbound water and may be polyphosphoric acid (116% phosphoric acid equivalents), 100% liquid phosphoric acid (prepared by heating phosphoric acid and phosphorus 25 pentoxide), or 100% orthophosphoric acid crystals, anhydrous or hemihydrate, which may be dissolved in the reaction mixture in combination with added water. With the crystals, the crystals may be pre-mixed with the other dry ingredients for use with the aqueous base in 30 preparing the subject product.
The calcium source may be varied, as to the anion, usually including in whole or at least in part carbonate. Usually, the carbonate will be present in at least about 30 formal percent, more usually at least 35 about 60 formal percent, and generally at least about 90 formal percent. Depending upon the choice of anion, different effects will be observed as to the nature of the product. Anions which may be employed include carbonate, oxide, hydroxide, chloride, fluoride, phosphate, e.g. tetracalcium phosphate, which anions may be incorporated into the final product, etc.
5 Calcium fluoride is relatively insoluble, so it will usually not be used as a source of fluoride. The oxides and hydroxides result in exothermicity and will be used sparingly. The hydroxide produces water and slows setting as well as providing exothermicity.
10 Halide will generally be present in an amount not to exceed 0.2 mole of halide per mole of calcium.
In selecting the calcium source, particularly where the calcium source not only serves as a source of calcium, but also in its neutralizing capacity, it may 15 also serve as a source of phosphate. Therefore, in providing the various combinations, one must consider what calcium phosphate product is desired, since for the most part, the resulting product will be dependent upon the ratio of calcium and phosphate in the 20 mixture. For brushite and monetite, a 1:1 ratio is desired. For octacalcium phosphate, a 1.33:1 ratio is desired. For tricalcium phosphate, a 1.5:1 ratio is desired. For hydroxyapatite, a 1.67:1 ratio is desired. The particular mineral will also be affected 25 by the pH, but since the pH of the mixture will generally be in the range of about 5-8, it is found that the calcium/phosphate ratio is overriding.
If desired, one may add small amounts of magnesium, which inhibits the formation of hydroxyapa-30 tite and favors the formation of a magnesium bearingform of tricalcium phosphate, called whitlockite.
Desirably less than about 10 mole percent of the calcium will be substituted by magnesium. Whitlockite has a substantially higher resorption rate as compared 35 to hydroxyapatite, usually resorbing over a period of about several months to a year.
For addition of the halides, fluoride and chloride, to form florapatite or chlorapatite, respectively, various sources of fluoride and chloride may be employed. Normally, the sources will either be soluble salts, such as calcium chloride, sodium or 5 calcium hexafluorosilicate INa2 or CaSiF6) or sodium fluoride, or may be added as dilute acids in the aqueous lubricant, generally less than about 1 M.
Usually at least about 5, more usually at least about 10~ of the hydroxyl groups will be replaced, and up to 100~.
With carbonate as the anion, the reaction tends to result in little, if any, heat rise, but there is substantial evolution of gas, which gas must be released during the mixing. Fluoride and chloride 15 serve to provide for a less resorbable product and a harder final product, in being included in the final crystal structure as florapatite or chlorapatite.
Where a basic anion is used, such as carbonate hydroxide or phosphate, these anions will serve to at 20 least partially neutralize the phosphoric acid.
As required, additional base will be added to neutralize the phosphoric acid. Normally, at least about 90~ of stoichiometric of base will be provided for neutralization of the acid. Desirably the pH of 25 the product in water will be in the range of about 5 to 9. By stoichiometric is intended available base, and not equivalence. That is, not all of the carbonate will be available for neutralization and, in some instances, it will be desirable to retain a proportion 30 of the product as carbonate, rather than as phos-phate. Thus, in determining the amount of additional neutralizing capacity, the amount of hydroxide, oxide or Ca4(PO4)2O employed will be calculated based on how much carbonate is to be retained in the product. The 35 neutralizing capacity will be desirably basic phosphates, although alkali or alkaline earth metal hydroxide, more particularly sodium or potassium, or combinations thereof, may be used. In choosing the various cations and anions, consideration must always be given as to whether the particular ion will be retained in the product and its effect on physiologic 5 acceptance and product properties. For the most part, the total concentration of alkali metals should be kept to a minimum.
The next ingredient is optional and is calcium mineral nuclei, particularly hydroxyapatite. The 10 source of the nuclei may be any physiologically acceptable source, such as ground bone, where the bone will be freed of undesirable organic matter, which could cause an immune or inflammatory reaction. The nuclei will generally be of a size in the range of about 1 mm to 10 ~, more usually 1 ~,m to 0.1 ~m.
Hydroxyapatite nuclei useful for the subject invention are commercially available, for example sioGel HTP, DNA
Grade, f rom ~io-Rad .
The water which is used will be substantially 20 pure, such as double distilled, deionized, or equivalent thereof. Other hydroxylic materials which are water miscible pharmacologically acceptable and do not interfere with the calcium phosphate formation, may also f ind use .
In many situations it may be desirable to include various bone associated proteins to modify the physical properties of the composition, enhance resorption, angiogenesis, cell entry and proliferation, mineralization, bone formation, growth of osteoclasts and/or osteoblasts, or the like. Proteins of particu-lar interest are the different types of collagen, particularly Type I. Other proteins include osteonectin, sialoproteins (BSP), ~-2HS-glycoproteins, bone-Gla-protein (BGP), matrix-Gla-protein, bone phosphoglycoprotein, bone phosphoprotein, bone proteoglycan, proteolipids, bone morphogenetic protein, cartilage induction factor, platelet derived growth factor, and skeletal growth factor. Other proteins associated with other parts of human or other mammalian anatomy, include proteins associated with cartilage, such as chondrocalcining proteins associated with dentin, such as phosphophoryn, glycoproteins and Gla proteins; associated with enamel, such as amelogenin, and enamelin.
Other proteins of interest include fibrin, fibrinogen, kerating tubulin, elastin and the like.
slood proteins may be employed, individually or together in plasma or serum.
While the ingredients can be added individu-ally, desirably, the dry ingredients may be combined for subsequent combination with the wet ingredients.
Thus, where orthophosphoric acid crystals are employed, these may be combined with a calcium source, and combined in appropriate proportions and mixed thoroughly to provide a dry uniform powder. The dry mixture may then be added to the aqueous base for reaction.
The amount of phosphoric acid will generally be about 6 to 15 parts, more usually from about 8 to 12 parts by weight. The calcium source will generally be f rom about 6 to 15, more usually f rom about 8 to 12 parts, generally not differing by more than about 0.8-1.2 parts per part of phosphoric acid source.
Particularly, where calcium carbonate and calcium hydroxide are employed, generally, the ratio of calcium carbonate to calcium hydroxide by weight will be about 4-10 :1, more usually 5-8 :1.
The calcium mineral crystal nuclei, if present, will generally vary from about 0.2 to 10 parts, more usually from about 0.5 to 6 parts by weight .
The amount of neutralizing capability or base which is employed will be dependent upon the amount of neutralization which is provided as the calcium source. Generally, the amount which is employed will vary from about 0.1 to 7 parts, more usually from about 1 to 6 parts.
The amount of water which is used, convenient-5 ly as the solvent for the neutralizing agent(s), willgenerally be from about 15 to 50, more usually from about 20 to 35 weight percent of the entire composition. The amount of water which is employed should be considered in light of the amount of calcium 10 hydroxide which is employed, which produces water in the neutralization of the phosphoric acid.
Various additional components may be included during the formation of the calcium phosphate mineral. Of particular interest are proteins involved 15 in skeletal structure. The protein may be added in f rom about 0 . 2 to 2 parts of protein as an aqueous dispersion or solution. Usually, the protein will be present in from about 1-10 wt % of the aqueous dispersion. The amount of water added as the protein 20 dispersion will be added in addition to the water of the aqueous base, where the total amount of water will come within the above limitations.
Various additives may be included to modify the physical structure. Various water soluble 25 physiologically acceptable materials may be included in minor amount. Sugars, such as sucrose, glucose or fructose, may be included to enhance porosity. The weight of the sugar will usually not exceed S wt % of the total solids.
The product is formed by combining the dry ingredients, either separately or pre-mixed, with the phosphoric acid and the aqueous media, neutralizing agent(s), protein, and other additives, as appro-priate. The mixture is thoroughly mixed over a relatively short time, so as to thoroughly distribute all of the reactants. Once the mixture is uniformly dispersed, the mixture may then be kneaded, continuing the process of reaction, releasing any gas which is formed, and shaping the product into an appropriate form. The kneading is over a relatively short time, usually not less than about 0 . S minutes and not more 5 than about 5 minutes, usually not more than about 2 minutes. Where the product is to be introduced in situ, it may be injected into the appropriate site, using a syringe or catheter, or packed in by other means, as appropriate.
The product is now allowed to set, during which time crystals grow and the product becomes an integral mass. While the product may harden almost immediately, usually the maturing process should take at least about 10 minutes, usually at least about lS 15 minutes, and not more than about 30 minutes, usually not more than about 25 minutes. Alternatively, where the material has been introduced at a site where it is to be retained, the material will naturally harden over time .
The subject products may be used for a variety of purposes, such as any form of connective tissue replacement, including bone cement, an injected prosthetic implant, a prosthetic orthopaedic or dental implant, as a root canal filler, a prophylactic injection to augment weak osteoporotic bone, or a vehicle for drug delivery. The composition may be used as a paste, being applied to a surface for adherence or holding some structure in place.
The subject compositions may be used with other materials to provide for specific types of properties. For example, fibrous materials may be employed, both organic and inorganic, such as silicon carbide whiskers, hydroxyapatite fibers, metallic fibers, or the like. See, for example, U.S. Patent No. 4,503,157.
Alternatively, various fillers may be employed, which may change the density of the material, add additional tensile strength, provide for enhanced 133249~

flexibility, or the like. Where a porous structure is desired, various additives may be included which may be leached out, so as to provide for porosity in the 5 mixture, in addition to any porosity achieved with the release of the gas formed during the reaction to produce the product. Porosity may also be achieved by the particular anions and cations employed, where alkali metal salts are produced which are readily 10 dissolved in the medium in which it is allowed to harden. Thus, by using calcium chloride and sodium or potassium hydroxide, the resulting salt will be water soluble and its dissolution will result in pathways through the structure. Similarly, one may include 15 various water soluble fibers, particles, or the like, in the composite structure, which may also be leached out to provide for porosity. Thus, the method of preparation allows for varying the characteristics of the f inal product .
The viscosity of the product may be varied depending on the application. The more basic the product (higher Ca/P ratio) the more the product will be hydroxyapatite, while the more acidic the product, the more the product will approach the properties of brushite. By varying the product crystal structure, percentage of solids, and presence of other additives, the viscosity may be selected to allow for ease of administration to the site to be treated.
Various considerations are associated with the physical characteristics of the product. Porosity may be increased by increasing the amount of lubricant in the paste, which occupies space in the final product, leaving behind a void or pore. Gas evolution from the paste may also create voids in the crystallizing product. Thus, porosity may be controlled by adjusting the amount of lubricant and gas evolution. For example, with calcium carbonate as a calcium source, porosity may be reduced by using dilute hydrochloric 1332~5 acid as the lubricant, where the reaction of the acid with the carbonate will result in gas evolution before the paste thickens. Thus, the CO2 will be lost before 5 the formation of the product, resulting in low porosity, while there will be little if any carbonate, to become incorporated into the final product. In general, as porosity increases, the compressive strength of the crystallized material decreases.
Porosity will not be the only parameter associated with compressive strength. Depending upon the other anions present in the final composition, compressive strength may vary by more than order of magnitude, while still having about the same 15 porosity. For example, a typical florapatite with 45%
porosity may have a compressive strength of 1,000 psi, whereas a carbonate apatite may have a compressive strength of 10,000 psi. Generally, florapatite have amorphous crystal morphologies, while carbonated 20 apatite generally has needle-like crystal morphologies.
Substantial changes in physical properties will be obtained by the addition of biopolymers such as collagen or other naturally-occurring structural protein. When adding collagen to the paste by being 25 present in the water solution, the crystallography of the final product is substantially unaffected, while the mechanical properties vary distinctively. The material appears viscoelastic, rather than having linear elasticity and brittleness, and appears to be 30 more abrasion resistant.
Kits may be provided to prepare the subject compositions. Thus, various of the ingredients may be premixed to form a powder which may then be combined with the phosphoric acid source and lubricant to 35 provide the final product. Generally, the kit may be comprised of the calcium source, which will include at least calcium carbonate, desirably tetracalcium phosphate, and to varying degrees, calcium oxide and/or hydroxide. These may be ground together to form a uniform mixture, where the particle size is not critical to this invention. Where other anions are to 5 be included, the mixture may also include a source of halide salt.
In a separate vessel, the phosphoric acid source will be provided, conveniently as crystals, or as phosphoric acid of at least about 100% substantially 10 free of uncombined water.
The following examples are offered by way of illustration and not by way of limitation.
EXPERIMENTAL
Example 1 S_ An alkaline solution was prepared of 4 . 5 9 of sodium hydroxide pellets in lS.0 ml of distilled 20 water . A powder was prepared of 9 . 8 9 of orthophos-phoric acid crystals, 8.0 9 of calcium carbonate, 1.5 9 of calcium hydroxide, and 5.0 9 of hydroxyapatite crystal nuclei. The powders were mixed and ground together until thoroughly dispersed. The 15 ml of 25 sodium hydroxide solution was poured into the mixed powders and mixed for about 1 to 2 min until a paste was formed. The mixture was formed into the desired shape and was then allowed to anneal for about 20 min, without being disturbed.
The product prepared as described above has the following characteristics:
- The mixture anneals to a hard, polycrystal-line, ceramic-like material.
- X-ray diffraction ~XRD) analysis of the material shows it to contain the following mineral phases:

1) Brushite (dibasic calcium phosphate, dihydrate) -- CaHPO4-2H2O;
2) Monetite (dibasic calcium phosphate) -- CaHPO4;
3 ) Octacalcium phosphate -- Ca8H2 ( PO4 ) 6 5H2O .
Example 2 B7 4/s7 4 -W
An alkaline solution was prepared of 5 . 4 9 of sodium hydroxide pellets in 19 . 0 ml of distilled water . A powder was prepared of 9 . 8 9 of orthophos-phoric acid crystals, 8.0 9 of calcium carbonate, 1.5 9 of calcium hydroxide, and 5.0 9 of hydroxyapatite crystal nuclei. The powders were mixed and ground together until thoroughly dispersed. The 19 ml of sodium hydroxide solution was poured into the mixed powders and mixed for about 1 to 2 min until a paste was formed. Some of the paste mixture was loaded into a 5 ml syringe and ejected from the syringe through a 14-gauge cannula to form ribbons of the paste. Some of the mixture was formed by hand into a desired shape.
The material was then allowed to anneal for about 20 min, without being disturbed. After annealing, some of the ribbon was placed in tap water to soak (B74-W).
The products prepared as described above have the following characteristics:
When initially mixed it is a paste which can be ejected through a standard syringe. Subsequent batches of this mixture have been injected into rats subcutaneously, intramuscularly and also into the intermedullary canal of rat femurs.
- The mixture anneals to a hard, polycrystal-line, ceramic-like material.
- X-ray diffraction (XRD) analysis of the material which was not placed in water shows it to contain the following mineral phases:

18 1~32~9~
1 ) Calcite -- CaCO3;
2) Hydroxyapatite -- Ca5(PO4)3(OH);
3) Dibasic Sodium Phosphate, dihydrate -- Na2HPo4-2H2o;
4) Sodium Bicarbonate -- NaHCO3.-X-ray diffraction (XRD) analysis of the material which was placed in water shows it to contain the following mineral phases:
1) Calcite -- CaCO3;
2) Hydroxyapatite -- Ca5~PO4)3(OH).
~xample 3 SB w/sioFibreTM
An alkaline solution was prepared of 5 . 4 9 of sodium hydroxide pellets in 19 . 0 ml of distilled water . A powder was prepared of 9 . 8 9 of orthophos-phoric acid crystals, 8.0 9 of calcium carbonate, 1.5 9 of calcium hydroxide, and 5.0 9 of BioFibreTM
(microcrystalline hydroxyapatite fibers). The powders were mixed and ground together until thoroughly dispersed. The 19 ml of sodium hydroxide solution was poured into the mixed powders and mixed for about 1 to 2 min until a paste was formed. The mixture was formed into the desired shape, and was then allowed to anneal for about 20 min, without being disturbed.
The products prepared as described above have the following characteristics:
- The mixture anneals to a hard, polycrystal-line, ceramic-like material, which feels stiffer than the material produced in Example 2.
Example 4 SB w/Collagen A slurry was prepared containing 0 . 6 9 of collagen for each 13.6 9 of distilled water, and heated at 35C for 1-2 days. An alkaline solution was prepared of 5 . 4 9 of sodium hydroxide pellets in 5 . 4 9 lg 1~2~9~
of distilled water. A powder was prepared of 9.8 9 of orthophosphoric acid crystals, 8.0 9 of calcium carbonate, 1.5 9 of calcium hydroxide, and 5.0 9 of 5 hydroxyapatite crystal nuclei. The powders were mixed and ground together until thoroughly dispersed, and then 14 . 2 9 of the collagen slurry was poured into the powders, followed by the 10.8 9 of sodium hydroxide solution. The solutions were mixed into the powders 10 for about 1 to 2 min until a paste was formed. The mixture was formed into the desired shape, and was then allowed to anneal for about 20 min, without being disturbed .
The products prepared as described above have 15 the following characteristics:
- The mixture anneals to a hard, polycrystal-line, ceramic-like material, which is tougher and more visco-elastic than the material produced in Example 2 (s74 recipe) and Example 3 (BioFibreTM recipe).
The compositions of the subject invention provide for a number of desirable properties. The compositions will set in a moist environment, for example, saliva, so that the compositions may be used for various purposes in the mouth. In addition, the subject compositions will set up and bond to a substrate in the presence of a substrate of bone serum, bone marrow and blood, where strong bonding character-istics are achieved between the underlying bony substrate and the subject compositions. In addition, no significant dimensional changes occur with the product during crystallization. Thus, one may form the product while moldable and the final form will have substantially the same dimensions. If some expansion is desired, one may use a gas evolving calcium source, so that the gas expansion provides for some expansion of the composition. Direct mechanical apposition is possible because of the injectable and moldable quality of the paste before it crystallizes. Chemical 133249~
apposition to bone occurs because as the paste forms in direct contact with like mineralogies of connective tissues, direct chemcial bonds form between the implant 5 the bone. Since the subject compositions are biocompatible, bone grows up to the implant and interdigitates with it.
The setting time can be varied by varying the amount of lubricant employed. Employing different 10 calicum sources can also have an effect on the rate of hardening, as well as the nature of the final product. The temperature of the reaction for the formation of the subject composition and temperature at which it may be introduced in vivo is controllable by 15 the particular choice of components. ~y varying the choice of phosphoric source and calcium source, the reaction may be endothermic, exothermic, or may be engineered to set up at room temperature or at body temperature (37C). In addition, for convenience, the 20 product may be provided as a kit, with the individual components may be gamma-sterilized at 3 . 5 MPa . If desired, alografted bone chips may be placed in the material to provide the product with bone inductive properties after mixing in vivo.
It is evident from the above results, that the subject methods and compositions provide a unique alternative to other methods for producing hydroxy-apatite. In accordance with this method, compositions can be produced which can be allowed to harden in situ, so as to be placed in position and fill any spaces.
The mixture will then harden to a shaped product which may then be modified, if desired, to fit a particular site, so that it may be machined, worked, or otherwise f ormed .

2, 133~49~

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications 10 may be practiced within the scope of the appended cla ims .

Claims (22)

1. A method for making calcium phosphate minerals comprising:
combining phosphoric acid substantially free of uncombined water, a calcium source, neutralizing anions including at least one of carbonate, phosphate and hydroxide in an amount sufficient to substantially neutralize said phosphoric acid and water in an amount to provide a kneadable mixture;
agitating the mixture to produce a substantially uniform mixture; and allowing the uniform mixture to set and become annealed to a hard workable structure.
2. A method according to claim 1, wherein calcium phosphate crystals are combined in said combining step.
3. A method according to claim 1, wherein said phosphoric acid is orthophosphoric acid crystals.
4. A method according to claim 3, wherein the neutralizing anions, orthophosphoric acid and calcium source are premixed prior to combining with water or the calcium source and water are precombined prior to combining with said phosphoric acid.
5. A method according to claim 1, wherein said calcium source is present at least in part as calcium carbonate.
6. A method according to claim 1, wherein a protein is combined in said combining step.
7. A method for making hydroxyapatite comprising:

combining orthophosphoric acid crystals, a neutralizing source comprising at least one of calcium carbonate, alkali metal hydroxide, calcium hydroxide and calcium phosphate, in an amount sufficient to provide a substantially neutral product, and water in an amount to provide a kneadable mixture;
agitating the mixture to produce a substantially uniform mixture; and allowing the uniform mixture to set and become matured to a hard workable structure.
8. A method according to claim 7, wherein said orthophosphoric acid crystals and neutralizing source are precombined in a uniform mixture.
9. A method according to claim 8, wherein said orthophosphoric acid crystals are present in 6-15 parts by weight, and said calcium carbonate is present in from about 6-15 parts by weight.
10. A method according to claim 7, wherein said maturing occurs in situ in bone.
11. A method according to claim 7, wherein a source of fluoride or chloride is included in said mixture to displace at least 10% of the hydroxyl groups of hydroxyapatite.
12. A method according to claim 7, wherein CaSiF6, Na2SiF6, NaF or CaCl2 is included in said mixture to displace at least 1096 of the hydroxyl groups of said hydroxyapatite.
13. A method according to claim 7, wherein 0.2-2 parts of collagen is combined in said combining step.
14. A method according to Claim 7, wherein dilute HF or HCl of less than about 1 molar is included with a carbonate anion calcium source, wherein said HF or HCl is in sufficient amount to displace at least 10% of the hydroxyl groups of said hydroxyapatite.
15. A calcium phosphate prepared according to claim 1.
16. An hydroxyapatite prepared according to claim 7.
17. An hydroxyapatite prepared according to claim 11.
18. A formed object of a calcium phosphate according to claim 15.
19. A formed object of an hydroxyapatite according to claim 16.
20. A formed object of an hydroxyapatite according to claim 17.
21. A formed object having a coating of a calcium phosphate according to claim 15.
22. A formed object according to claim 21, wherein said calcium phosphate comprises a protein.
CA000597140A 1988-04-20 1989-04-19 In situ calcium phosphate minerals -- method and composition Expired - Lifetime CA1332495C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US183,770 1988-04-20
US07/183,770 US4880610A (en) 1988-04-20 1988-04-20 In situ calcium phosphate minerals--method and composition

Publications (1)

Publication Number Publication Date
CA1332495C true CA1332495C (en) 1994-10-18

Family

ID=22674214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000597140A Expired - Lifetime CA1332495C (en) 1988-04-20 1989-04-19 In situ calcium phosphate minerals -- method and composition

Country Status (5)

Country Link
US (3) US4880610A (en)
EP (1) EP0347028B1 (en)
JP (1) JP2863544B2 (en)
CA (1) CA1332495C (en)
DE (1) DE68928816T2 (en)

Families Citing this family (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053212A (en) * 1988-04-20 1991-10-01 Norian Corporation Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
US5962028A (en) * 1988-04-20 1999-10-05 Norian Corporation Carbonated hydroxyapatite compositions and uses
US6002065A (en) * 1988-04-20 1999-12-14 Norian Corporation Kits for preparing calcium phosphate minerals
US5129905A (en) * 1988-04-20 1992-07-14 Norian Corporation Methods for in situ prepared calcium phosphate minerals
US5047031A (en) * 1988-04-20 1991-09-10 Norian Corporation In situ calcium phosphate minerals method
GB8813033D0 (en) * 1988-06-02 1988-07-06 Geistlich Soehne Ag Chemical compound
US5275564A (en) * 1988-08-25 1994-01-04 American Dental Laser, Inc. Dental laser assembly
US5009898A (en) * 1988-09-29 1991-04-23 Kabushiki Kaisha Sangi Antimicrobial hydroxyapatite powders and methods for preparing them
US5034059A (en) * 1989-02-17 1991-07-23 Norian Corporation Composition comprising octacalcium phosphate crystals and polypeptide
US5037639A (en) * 1989-05-24 1991-08-06 American Dental Association Health Foundation Methods and compositions for mineralizing calcified tissues
US5460803A (en) * 1989-05-24 1995-10-24 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5534244A (en) * 1989-05-24 1996-07-09 Tung; Ming S. Methods and compositions for mineralizing and/or fluoridating calcified tissues with amorphous strontium compounds
US5322675A (en) * 1990-11-09 1994-06-21 Director-General Of Agency Of Industrial Science And Technology Method of preparing calcium phosphate
US5164187A (en) * 1990-04-05 1992-11-17 Norian Corporation Hydroxyapatite prosthesis coatings
CA2088169C (en) * 1990-07-27 2002-04-23 Brent R. Constantz Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
US5231169A (en) * 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5310464A (en) * 1991-01-04 1994-05-10 Redepenning Jody G Electrocrystallization of strongly adherent brushite coatings on prosthetic alloys
US5205921A (en) * 1991-02-04 1993-04-27 Queen's University At Kingston Method for depositing bioactive coatings on conductive substrates
JPH06315629A (en) * 1991-11-15 1994-11-15 Central Glass Co Ltd Filler for deproteinization and cartridge filled with the same
ES2174828T3 (en) * 1991-12-30 2002-11-16 Norian Corp MINERALIZED COLLAGEN.
US5258044A (en) * 1992-01-30 1993-11-02 Etex Corporation Electrophoretic deposition of calcium phosphate material on implants
US5270351A (en) * 1992-06-15 1993-12-14 American Dental Association Health Foundation Adhesion-promoting agents incorporating polyvalent cations
US5944721A (en) * 1997-12-08 1999-08-31 Huebner; Randall J. Method for repairing fractured bone
US5522893A (en) * 1993-03-12 1996-06-04 American Dental Association Health Foundation Calcium phosphate hydroxyapatite precursor and methods for making and using the same
US5427768A (en) * 1993-06-23 1995-06-27 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
WO1995003369A1 (en) * 1993-07-22 1995-02-02 Norian Corporation Storage stable partially neutralized acid compositions and uses
US5476647A (en) * 1993-09-13 1995-12-19 American Dental Association Health Foundation Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets
US5525148A (en) * 1993-09-24 1996-06-11 American Dental Association Health Foundation Self-setting calcium phosphate cements and methods for preparing and using them
US5472734A (en) * 1993-09-29 1995-12-05 Aluminum Company Of America Apatite coating on aluminum sheet and method of manufacture
US5514137A (en) * 1993-12-06 1996-05-07 Coutts; Richard D. Fixation of orthopedic devices
US5503164A (en) * 1994-01-28 1996-04-02 Osteogenics, Inc. Device and method for repair of craniomaxillofacial bone defects including burr holes
US20050043808A1 (en) * 1994-05-06 2005-02-24 Advanced Bio Surfaces, Inc. Knee joint prosthesis
US5556429A (en) * 1994-05-06 1996-09-17 Advanced Bio Surfaces, Inc. Joint resurfacing system
US5496399A (en) * 1994-08-23 1996-03-05 Norian Corporation Storage stable calcium phosphate cements
US5678233A (en) * 1994-09-14 1997-10-14 Brown; Paul W. Method of immobilizing toxic or radioactive inorganic wastes and associated products
AU713540B2 (en) * 1994-10-25 1999-12-02 Osteonics Corp. Interlocking structural elements and method for bone repair, augmentation and replacement
US5550172A (en) * 1995-02-07 1996-08-27 Ethicon, Inc. Utilization of biocompatible adhesive/sealant materials for securing surgical devices
US5624493A (en) * 1995-04-19 1997-04-29 The United States Of America As Represented By The Department Of Energy Quick-setting concrete and a method for making quick-setting concrete
US6287341B1 (en) 1995-05-19 2001-09-11 Etex Corporation Orthopedic and dental ceramic implants
US6027742A (en) * 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US6117456A (en) * 1995-05-19 2000-09-12 Etex Corporation Methods and products related to the physical conversion of reactive amorphous calcium phosphate
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US5676976A (en) * 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US7150879B1 (en) 1995-05-19 2006-12-19 Etex Corporation Neutral self-setting calcium phosphate paste
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US5652056A (en) * 1995-08-25 1997-07-29 Pepin; John N. Hydroxyapatite filament
US5648097A (en) * 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US5783217A (en) * 1995-11-07 1998-07-21 Etex Corporation Low temperature calcium phosphate apatite and a method of its manufacture
DE19613081A1 (en) * 1996-04-02 1997-10-09 Franz Prof Dr Med Copf Prosthesis part for a stem prosthesis and material kit for use with such
US6143948A (en) * 1996-05-10 2000-11-07 Isotis B.V. Device for incorporation and release of biologically active agents
DE69716505T2 (en) * 1996-05-10 2003-06-26 Isotis Nv Implant material and process for its manufacture
FR2749756B1 (en) * 1996-06-14 1998-09-11 Bioland PROCESS FOR THE PREPARATION OF AN IMPLANTABLE COMPOSITE MATERIAL, MATERIAL OBTAINED, IMPLANT COMPRISING SUCH MATERIAL, AND IMPLEMENTATION KIT
US6953594B2 (en) 1996-10-10 2005-10-11 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US8728536B2 (en) 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
JP4781494B2 (en) * 1996-10-16 2011-09-28 エテックス コーポレイション Process for producing imperfect crystalline calcium phosphate and its use
ATE381314T1 (en) 1996-10-16 2008-01-15 Etex Corp BIOCERAMIC COMPOSITION
EP1230902A1 (en) 1996-11-15 2002-08-14 Advanced Bio Surfaces, Inc. Biomaterial system for in situ tissue repair
US5939039A (en) * 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
AU1527099A (en) * 1998-01-09 1999-07-26 Enamelon, Inc. Solid products and methods for the remineralization and prevention of demineralization of teeth
US6139585A (en) * 1998-03-11 2000-10-31 Depuy Orthopaedics, Inc. Bioactive ceramic coating and method
US6736849B2 (en) 1998-03-11 2004-05-18 Depuy Products, Inc. Surface-mineralized spinal implants
DE19816858A1 (en) 1998-04-16 1999-10-21 Merck Patent Gmbh Tricalcium phosphate-containing bio-cement pastes with cohesion promoters
KR100563476B1 (en) * 1998-07-03 2006-03-27 이진용 Bone regeneration material
US5968253A (en) * 1998-07-31 1999-10-19 Norian Corporation Calcium phosphate cements comprising antimicrobial agents
DE59903490D1 (en) * 1998-09-11 2003-01-02 Schmidmaier Gerhard BIOLOGICALLY ACTIVE IMPLANTS
ES2185227T3 (en) * 1998-10-19 2003-04-16 Synthes Ag CERAMIC HYDRAULIC CEMENT THAT TURNS.
US6224635B1 (en) * 1998-11-06 2001-05-01 Hospital For Joint Diseases Implantation of surgical implants with calcium sulfate
US6383519B1 (en) * 1999-01-26 2002-05-07 Vita Special Purpose Corporation Inorganic shaped bodies and methods for their production and use
US7270705B2 (en) 1999-07-14 2007-09-18 Jiin-Huey Chern Lin Method of increasing working time of tetracalcium phosphate cement paste
US6960249B2 (en) * 1999-07-14 2005-11-01 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface
US7094282B2 (en) * 2000-07-13 2006-08-22 Calcitec, Inc. Calcium phosphate cement, use and preparation thereof
US6840995B2 (en) * 1999-07-14 2005-01-11 Calcitec, Inc. Process for producing fast-setting, bioresorbable calcium phosphate cements
US6379453B1 (en) 1999-07-14 2002-04-30 Jiin-Huey Chern Process for producing fast-setting, bioresorbable calcium phosphate cements
US7169373B2 (en) * 1999-07-14 2007-01-30 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface and process for preparing the same
US6458162B1 (en) * 1999-08-13 2002-10-01 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
DE19938704C1 (en) 1999-08-14 2001-10-31 Ivoclar Vivadent Ag Process for the production of reaction systems for implantation in the human and animal body as a bone substitute, which i.a. Contain calcium and phosphorus
US6458763B1 (en) * 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
WO2001054746A2 (en) 2000-01-31 2001-08-02 Advanced Research And Technology Institute, Inc. Composite biomaterial including anisometric calcium phosphate reinforcement particles
US6723334B1 (en) * 2000-03-01 2004-04-20 Iowa State University Research Foundation, Inc. Biologically compatible bone cements and orthopedic methods
US6630153B2 (en) * 2001-02-23 2003-10-07 Smith & Nephew, Inc. Manufacture of bone graft substitutes
US7156915B2 (en) * 2000-07-13 2007-01-02 Calcitec, Inc. Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US7160382B2 (en) * 2000-07-13 2007-01-09 Calcitec, Inc. Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
TWI291352B (en) * 2000-07-13 2007-12-21 Calcitec Inc Calcium phosphate cement, use and preparation thereof
US6551273B1 (en) 2000-08-23 2003-04-22 Scimed Life Systems, Inc. Catheter having a shaft keeper
JP2004521666A (en) 2000-08-28 2004-07-22 アドバンスト バイオ サーフェイシズ,インコーポレイティド Methods and systems for enhancing mammalian joints
US6679886B2 (en) 2000-09-01 2004-01-20 Synthes (Usa) Tools and methods for creating cavities in bone
US6599516B1 (en) 2000-09-14 2003-07-29 Etex Corporation Malleable implant containing solid element that resorbs or fractures to provide access channels
JP2004511320A (en) * 2000-10-16 2004-04-15 ユニバーシテイ・オブ・サウス・カロライナ Biocompatible cement containing reactive calcium phosphate nanoparticles and methods of making and using said cement
US6736799B1 (en) 2000-10-24 2004-05-18 Vita Licensing, Inc. Delivery device for biological composites and method of preparation thereof
US7052517B2 (en) * 2000-10-24 2006-05-30 Vita Special Purpose Corporation Delivery device for biological composites and method of preparation thereof
US6547866B1 (en) * 2000-10-30 2003-04-15 Howmedica Osteonics Corp. Porous calcium phosphate cement
DE10057616B4 (en) 2000-11-21 2006-09-14 Stryker Trauma Gmbh Method for mixing and applying flowable bone cement and bone cement mixing device
US20020114795A1 (en) 2000-12-22 2002-08-22 Thorne Kevin J. Composition and process for bone growth and repair
US6558709B2 (en) 2001-01-05 2003-05-06 Howmedica Osteonics Corp. Calcium phosphate composition and method of preparing same
US7294187B2 (en) * 2001-01-24 2007-11-13 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US7709029B2 (en) * 2001-01-24 2010-05-04 Ada Foundation Calcium-containing restoration materials
US6793725B2 (en) 2001-01-24 2004-09-21 Ada Foundation Premixed calcium phosphate cement pastes
US6592251B2 (en) 2001-01-26 2003-07-15 Howmedica Osteonics Corp. Cement mixing and dispensing device
US6494611B2 (en) 2001-01-26 2002-12-17 Howmedica Osteonics Corp. Apparatus for mixing a liquid and dry powdered components
CA2442855A1 (en) * 2001-04-12 2002-10-24 Therics, Inc. Method and apparatus for engineered regenerative biostructures
US7235079B2 (en) 2004-11-18 2007-06-26 Acumed Llc Composite bone fasteners
US6616742B2 (en) 2001-08-30 2003-09-09 Cana Lab Corporation Process for preparing a paste from calcium phosphate cement
DE10161827A1 (en) * 2001-12-15 2003-06-26 Dot Gmbh Coating of substrates with calcium phosphate, useful for producing bone substitutes, comprises applying a calcium phosphate gel to the substrate
GB2399309A (en) * 2001-12-19 2004-09-15 Advanced Bio Surfaces Inc Bone smoothing method and system
US6840961B2 (en) * 2001-12-21 2005-01-11 Etex Corporation Machinable preformed calcium phosphate bone substitute material implants
CA2473858A1 (en) * 2002-01-22 2003-07-31 Advanced Bio Surfaces, Inc. Interpositional arthroplasty system and method
KR20030070713A (en) * 2002-02-26 2003-09-02 김현만 Method for preparing thin film of calcium phosphate crystals on the solid surfaces
US7514249B2 (en) * 2002-04-18 2009-04-07 The University Of Florida Research Foundation, Inc. Biomimetic organic/inorganic composites
US7455854B2 (en) * 2002-04-18 2008-11-25 University Of Florida Research Foundation, Inc. Method for producing a mineral fiber
US7514248B2 (en) 2002-04-18 2009-04-07 University Of Florida Research Foundation, Inc. Process for making organic/inorganic composites
US20030216777A1 (en) * 2002-05-16 2003-11-20 Yin-Chun Tien Method of enhancing healing of interfacial gap between bone and tendon or ligament
CA2487994C (en) * 2002-06-19 2011-11-01 Marc Bohner Hydraulic cement based on calcium phosphate for surgical use
ES2309350T3 (en) * 2002-07-11 2008-12-16 Advanced Bio Surfaces, Inc. METHOD AND EQUIPMENT FOR INTERPOSITIONAL ARTROPLASTY.
NZ538196A (en) * 2002-08-12 2007-05-31 Osteotech Inc Synthesis of a bone-polymer composite material for forming osteoimplants
GB0222291D0 (en) * 2002-09-26 2002-10-30 Smith & Nephew Adhesive bone cement
IL153699A (en) * 2002-12-26 2008-11-26 Prochon Biotech Ltd Bone graft composite
US20050251267A1 (en) * 2004-05-04 2005-11-10 John Winterbottom Cell permeable structural implant
US9107751B2 (en) 2002-12-12 2015-08-18 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
US20040141903A1 (en) * 2003-01-17 2004-07-22 Howmedica Osteonics Corp. Calcium phosphate cement precursors
FR2850282B1 (en) * 2003-01-27 2007-04-06 Jerome Asius INJECTABLE IMPLANT BASED ON CERAMIC FOR THE FILLING OF WRINKLES, CUTANEOUS DEPRESSIONS AND SCARS, AND ITS PREPARATION
US7985414B2 (en) * 2003-02-04 2011-07-26 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
CA2514336C (en) 2003-02-04 2013-05-14 Osteotech, Inc. Polyurethanes for osteoimplants
US7507257B2 (en) * 2003-02-04 2009-03-24 Wright Medical Technology, Inc. Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects
EP3254710B1 (en) 2003-04-11 2019-05-22 Etex Corporation Osteoinductive bone material
US7067169B2 (en) * 2003-06-04 2006-06-27 Chemat Technology Inc. Coated implants and methods of coating
US20040250730A1 (en) * 2003-06-12 2004-12-16 David Delaney Calcium phosphate cements prepared from silicate-phosphate solutions
US20040254668A1 (en) * 2003-06-16 2004-12-16 Jang Bor Z. Macro-porous hydroxyapatite scaffold compositions and freeform fabrication method thereof
US20040250729A1 (en) * 2003-06-16 2004-12-16 Jang Bor Z. Fast-setting carbonated hydroxyapatite compositions and uses
US20040262809A1 (en) * 2003-06-30 2004-12-30 Smith Todd S. Crosslinked polymeric composite for orthopaedic implants
IL156945A0 (en) * 2003-07-15 2004-02-08 Itzhak Tavori Device and a method for orthopedic delivery of bone reconstruction medium
US7163651B2 (en) * 2004-02-19 2007-01-16 Calcitec, Inc. Method for making a porous calcium phosphate article
US7118705B2 (en) * 2003-08-05 2006-10-10 Calcitec, Inc. Method for making a molded calcium phosphate article
TWI275386B (en) * 2003-08-05 2007-03-11 Cana Lab Corp Methods for preparing medical implants from calcium phosphate cement and medical implants
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US8029755B2 (en) 2003-08-06 2011-10-04 Angstrom Medica Tricalcium phosphates, their composites, implants incorporating them, and method for their production
WO2005027988A2 (en) * 2003-09-05 2005-03-31 Norian Corporation Bone cement compositions having fiber-reinforcement and/or increased flowability
BRPI0414843A (en) * 2003-09-30 2006-11-21 John Arthur Disegi antimicrobial hyaluronic acid coatings for orthopedic implants
US9199005B2 (en) * 2003-10-01 2015-12-01 New York University Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate
US7419680B2 (en) 2003-10-01 2008-09-02 New York University Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate
WO2005037137A2 (en) * 2003-10-17 2005-04-28 Therics, Inc. Spinal cage insert, filler piece and method of manufacturing
CA2545185A1 (en) * 2003-11-07 2005-05-26 Calcitec, Inc. Spinal fusion procedure using an injectable bone substitute
CA2550431A1 (en) 2003-12-19 2005-07-14 Osteotech, Inc. Tissue-derived mesh for orthopedic regeneration
US8328876B2 (en) * 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8012210B2 (en) 2004-01-16 2011-09-06 Warsaw Orthopedic, Inc. Implant frames for use with settable materials and related methods of use
AU2005210630A1 (en) * 2004-01-30 2005-08-18 Warsaw Orthopedic, Inc. Stacking implants for spinal fusion
US7189263B2 (en) * 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7351280B2 (en) * 2004-02-10 2008-04-01 New York University Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment
AU2005249365B2 (en) 2004-04-15 2011-04-07 Etex Corporation Delayed-setting calcium phosphate pastes
US9220595B2 (en) 2004-06-23 2015-12-29 Orthovita, Inc. Shapeable bone graft substitute and instruments for delivery thereof
US7384430B2 (en) 2004-06-30 2008-06-10 Depuy Products, Inc. Low crystalline polymeric material for orthopaedic implants and an associated method
ES2246726B2 (en) 2004-08-12 2007-11-01 Universitat Politecnica De Catalunya SELF-FRAGABLE AND INJECTABLE CALCIUM PHOSPHATE FOAM
US7785648B2 (en) * 2004-09-22 2010-08-31 New York University Adherent apatite coating on titanium substrate using chemical deposition
US20060110422A1 (en) * 2004-11-19 2006-05-25 Tas Ahmet C Conversion of calcite powders into macro- and microporous calcium phosphate scaffolds for medical applications
US20060282169A1 (en) * 2004-12-17 2006-12-14 Felt Jeffrey C System and method for upper extremity joint arthroplasty
US7883653B2 (en) 2004-12-30 2011-02-08 Depuy Products, Inc. Method of making an implantable orthopaedic bearing
US7896921B2 (en) 2004-12-30 2011-03-01 Depuy Products, Inc. Orthopaedic bearing and method for making the same
US7879275B2 (en) 2004-12-30 2011-02-01 Depuy Products, Inc. Orthopaedic bearing and method for making the same
US8480629B2 (en) 2005-01-28 2013-07-09 Boston Scientific Scimed, Inc. Universal utility board for use with medical devices and methods of use
US7267690B2 (en) 2005-03-09 2007-09-11 Vertebral Technologies, Inc. Interlocked modular disc nucleus prosthesis
US7416602B2 (en) * 2005-04-08 2008-08-26 Howmedica Leibinger, Inc. Calcium phosphate cement
US7459018B2 (en) * 2005-04-08 2008-12-02 Howmedica Leibinger Inc. Injectable calcium phosphate cement
US8814567B2 (en) 2005-05-26 2014-08-26 Zimmer Dental, Inc. Dental implant prosthetic device with improved osseointegration and esthetic features
JP5438967B2 (en) 2005-08-30 2014-03-12 ジマー デンタル, インコーポレイテッド Dental implant with improved osseointegration features
US8562346B2 (en) 2005-08-30 2013-10-22 Zimmer Dental, Inc. Dental implant for a jaw with reduced bone volume and improved osseointegration features
CN103349793B (en) 2005-09-09 2016-02-10 阿格诺沃斯健康关爱公司 Composite bone graft substitute cement and the goods obtained by it
US8025903B2 (en) 2005-09-09 2011-09-27 Wright Medical Technology, Inc. Composite bone graft substitute cement and articles produced therefrom
US8921109B2 (en) 2005-09-19 2014-12-30 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
WO2007053850A2 (en) 2005-11-01 2007-05-10 Osteotech, Inc. Bone matrix compositions and methods
EP1962914B1 (en) 2005-11-14 2019-02-27 Biomet 3i, LLC Deposition of discrete nanoparticles on an implant surface
US20070122445A1 (en) * 2005-11-28 2007-05-31 Shalaby Shalaby W Absorbable fatigue-enduring phosphate composites
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
EP1976459A4 (en) 2006-01-19 2012-06-20 Warsaw Orthopedic Inc Porous osteoimplant
CZ301206B6 (en) * 2006-01-19 2009-12-09 Ceská hlava s.r.o. Composition for prevention and curing of the initial tooth caries
US20070185495A1 (en) * 2006-01-30 2007-08-09 Howmedica International S. De R. L. Plug-in syringe stand
US20100131064A1 (en) * 2006-04-05 2010-05-27 University Of Nebraska Bioresorbable polymer reconstituted bone and methods of formation thereof
EP2010193A4 (en) * 2006-04-17 2012-07-25 Hepacore Ltd Methods for bone regeneration using endothelial progenitor cell preparations
US8048118B2 (en) * 2006-04-28 2011-11-01 Warsaw Orthopedic, Inc. Adjustable interspinous process brace
EP2422822A1 (en) 2006-06-29 2012-02-29 Orthovita, Inc. Bioactive bone graft substitute
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
EP1917924A1 (en) * 2006-11-02 2008-05-07 Stryker Trauma GmbH Implantation device
US8388626B2 (en) * 2006-11-08 2013-03-05 Warsaw Orthopedic, Inc. Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device
US9737414B2 (en) 2006-11-21 2017-08-22 Vertebral Technologies, Inc. Methods and apparatus for minimally invasive modular interbody fusion devices
DE102006058669B4 (en) * 2006-12-13 2009-04-09 Kaczmarek, André, Dr. Tri-calcium phosphate and / or hydroxylapatite-containing self-curing repair material for iatrogenic injuries of tooth tissues with a polyphosphate matrix and a calcium hydroxide-containing medium
US7718616B2 (en) 2006-12-21 2010-05-18 Zimmer Orthobiologics, Inc. Bone growth particles and osteoinductive composition thereof
US8926623B2 (en) * 2007-01-12 2015-01-06 Warsaw Orthopedic, Inc. System and method for forming porous bone filling material
US8268010B2 (en) * 2007-01-12 2012-09-18 Warsaw Orthopedic, Inc. System and method for forming bone filling materials with microparticles
US8840618B2 (en) * 2007-01-12 2014-09-23 Warsaw Orthopedic, Inc. System and method for pressure mixing bone filling material
EP1958649A1 (en) * 2007-02-14 2008-08-20 Graftys Injectable calcium-phosphate cement releasing a bone resorption inhibitor
US9764057B2 (en) 2007-06-06 2017-09-19 Innotere Gmbh Hydraulic cement-based implant material and use thereof
CA2945295C (en) 2007-06-15 2020-01-14 Warsaw Orthopedic, Inc. Method of treating tissue
WO2008157492A2 (en) 2007-06-15 2008-12-24 Osteotech, Inc. Osteoinductive demineralized cancellous bone
CA2690457C (en) 2007-06-15 2018-02-20 Osteotech, Inc. Bone matrix compositions and methods
US9554920B2 (en) 2007-06-15 2017-01-31 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
US9492278B2 (en) 2007-07-10 2016-11-15 Warsaw Orthopedic, Inc. Delivery system
US9149345B2 (en) 2007-08-30 2015-10-06 Zimmer Dental, Inc. Multiple root implant
US8202539B2 (en) * 2007-10-19 2012-06-19 Warsaw Orthopedic, Inc. Demineralized bone matrix compositions and methods
EP2217293B1 (en) 2007-11-09 2019-05-22 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
JP5806466B2 (en) 2008-01-28 2015-11-10 バイオメット・3アイ・エルエルシー Implant surface with improved hydrophilicity
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
CA2719798A1 (en) * 2008-03-28 2009-10-01 Osteotech, Inc. Bone anchors for orthopedic applications
US20110125158A1 (en) 2008-05-01 2011-05-26 Ashish Dhar Diwan Systems, methods and apparatuses for formation and insertion of tissue prostheses
US9095396B2 (en) 2008-07-02 2015-08-04 Zimmer Dental, Inc. Porous implant with non-porous threads
US8562348B2 (en) 2008-07-02 2013-10-22 Zimmer Dental, Inc. Modular implant with secured porous portion
US8899982B2 (en) 2008-07-02 2014-12-02 Zimmer Dental, Inc. Implant with structure for securing a porous portion
US8231387B2 (en) 2008-07-02 2012-07-31 Zimmer, Inc. Porous implant with non-porous threads
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2012134540A2 (en) 2010-10-22 2012-10-04 Vanderbilt University Injectable synthetic pur composite
US9333276B2 (en) * 2008-10-30 2016-05-10 Vanderbilt University Bone/polyurethane composites and methods thereof
US20100114314A1 (en) 2008-11-06 2010-05-06 Matthew Lomicka Expandable bone implant
KR101769805B1 (en) 2008-11-12 2017-08-21 스트리커 디벨롭먼트, 엘엘씨 Tetra calcium phosphate based organophosphorus compositions and methods
US9011537B2 (en) 2009-02-12 2015-04-21 Warsaw Orthopedic, Inc. Delivery system cartridge
US8623311B2 (en) * 2009-03-03 2014-01-07 Graftys Gallium-doped phosphocalcic compounds
US8894958B2 (en) * 2009-03-03 2014-11-25 Centre National De La Recherche Scientifique (C.N.R.S.) Galliated calcium phosphate biomaterials
EP2228080A1 (en) 2009-03-03 2010-09-15 Graftys Galliated calcium phosphate biomaterials
US9707058B2 (en) 2009-07-10 2017-07-18 Zimmer Dental, Inc. Patient-specific implants with improved osseointegration
EP3342432B1 (en) 2009-08-03 2021-07-07 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US8602782B2 (en) 2009-11-24 2013-12-10 Zimmer Dental, Inc. Porous implant device with improved core
CA2784533C (en) 2009-12-18 2016-02-09 Howmedica Osteonics Corp. Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same
US20110151027A1 (en) * 2009-12-21 2011-06-23 Theodore D Clineff Strontium-doped calcium phosphate bone graft materials
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US8641418B2 (en) 2010-03-29 2014-02-04 Biomet 3I, Llc Titanium nano-scale etching on an implant surface
CA3048850A1 (en) 2010-05-11 2011-11-17 Howmedica Osteonics Corp. Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods
TWI579007B (en) 2010-07-02 2017-04-21 艾格諾福斯保健公司 Use of bone regenerative material
CA2809606C (en) 2010-08-26 2020-12-01 University Of Louisville Research Foundation, Inc. Compositions and methods for treating bone defects
MA33231B1 (en) 2010-09-20 2012-05-02 Univ Hassan Ii Mohammedia BIOVERRE-BASED MACROPOROUS CEMENTS, BIOACTIVE, BIORESORBABLE FOR BIOMEDICAL USE
ES2714701T3 (en) 2010-11-10 2019-05-29 Stryker European Holdings I Llc Process for the preparation of a polymeric bone foam
US8613938B2 (en) 2010-11-15 2013-12-24 Zimmer Orthobiologics, Inc. Bone void fillers
WO2012078671A2 (en) * 2010-12-06 2012-06-14 Massachusetts Institute Of Technology Tricalcium phosphate binding peptides and use thereof
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
WO2012129234A1 (en) 2011-03-21 2012-09-27 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
WO2012158527A2 (en) 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
US9510953B2 (en) 2012-03-16 2016-12-06 Vertebral Technologies, Inc. Modular segmented disc nucleus implant
US9131995B2 (en) 2012-03-20 2015-09-15 Biomet 3I, Llc Surface treatment for an implant surface
WO2014047061A1 (en) 2012-09-18 2014-03-27 Endo Pharmaceuticals Inc. Urethral anastomosis device
US20160074041A1 (en) 2013-03-14 2016-03-17 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
CN103204485B (en) * 2013-04-25 2015-02-11 连云港树人科创食品添加剂有限公司 Production method of food grade tricalcium phosphate
CA2926421C (en) 2013-10-08 2022-05-03 Vivorte, Inc. Processed bone particle compositions and related methods
US9168114B2 (en) 2013-10-17 2015-10-27 B & D Dental Corp. Method of making a dental prosthesis
FR3021045B1 (en) * 2014-05-16 2020-02-21 Solvay Sa PROCESS FOR PRODUCING A PHOSPHOCALCIC REAGENT, REAGENT OBTAINED AND ITS USE
ES2555235B1 (en) * 2014-06-25 2016-10-05 Universitat Politècnica De Catalunya New one-step manufacturing process of foamed biomaterials
US9820792B2 (en) 2014-08-22 2017-11-21 Kyphon SÀRL Bone cement mixing and delivery device
US9820791B2 (en) 2014-08-22 2017-11-21 Kyphon SÀRL Methods of filling bone using bone cement mixing and delivery devices
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
US10219986B2 (en) 2015-03-04 2019-03-05 Modern Ideas LLC Stabilized calcium phosphate and methods of forming same
US11020160B2 (en) * 2016-03-21 2021-06-01 Warsaw Orthopedic, Inc. Surgical injection system and method
EP3231453B1 (en) 2016-04-14 2019-12-25 Immundiagnostik AG Bone sialoprotein(bsp)-functionalised bone replacement bodies
WO2019051260A1 (en) 2017-09-08 2019-03-14 Pioneer Surgical Technology, Inc. Intervertebral implants, instruments, and methods
USD907771S1 (en) 2017-10-09 2021-01-12 Pioneer Surgical Technology, Inc. Intervertebral implant
BR112021006752A2 (en) 2018-10-12 2021-07-13 Theradaptive, Inc. polypeptides including a tricalcium beta phosphate binding sequence and uses thereof
BR112022006827A2 (en) * 2019-10-09 2022-07-05 Solidia Technologies Inc METHODS FOR FORMING COMPOUND MATERIALS CURED WITH OPTIMIZED PH AND RELATED COMPOSITIONS AND SYSTEMS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2012436A (en) * 1932-09-06 1935-08-27 Southern Mineral Products Corp Process of making monocalcium phosphate
DE1206293B (en) * 1960-01-16 1965-12-02 Knapsack Ag Process for the production of a mineral feed consisting essentially of dicalcium phosphate
US3379541A (en) * 1964-02-18 1968-04-23 Monsanto Co Alkaline earth metal hydroxylapatites, processes for preparing the same and compositions containing the same
DE1259861B (en) * 1965-06-16 1968-02-01 Knapsack Ag Process for the preparation of stabilized dicalcium phosphate dihydrate
US3467495A (en) * 1965-12-23 1969-09-16 Int Minerals & Chem Corp Preparation of calcium phosphates
GB1111216A (en) * 1966-02-04 1968-04-24 Albright & Wilson Mfg Ltd Production of alkali metal phosphates
US3647371A (en) * 1968-08-07 1972-03-07 Monsanto Co Method for preparation of dicalcium phosphate
GB1395037A (en) * 1972-10-10 1975-05-21 Doulton & Co Ltd Bone china
US4048300A (en) * 1973-01-11 1977-09-13 Colgate-Palmolive Company Dental preparation containing materials having calcium and phosphate components
GB1450157A (en) * 1973-03-06 1976-09-22 Colgate Palmolive Co Dental powder cement and filling material
US4101637A (en) * 1975-10-29 1978-07-18 J. R. Simplot Company Direct granulation process for triple superphosphate
JPS5946911B2 (en) * 1976-12-16 1984-11-15 住友化学工業株式会社 implant
US4274879A (en) * 1979-03-05 1981-06-23 Tate & Lyle Limited Synthetic bone ash
JPS5654841A (en) * 1979-10-08 1981-05-15 Mitsubishi Mining & Cement Co Bone broken portion and filler for void portion and method of treating bone of animal using said filler
US4324772A (en) * 1980-11-19 1982-04-13 Monsanto Company Process for producing hydroxyapatite
USRE33161E (en) * 1982-04-29 1990-02-06 American Dental Association Health Foundation Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements
US4518430A (en) * 1982-04-29 1985-05-21 American Dental Association Health Foundation Dental resptorative cement pastes
GB2129410B (en) * 1982-11-04 1986-11-12 Baslini Ind Chim Production of calcium phosphates
SU1331501A1 (en) * 1983-06-22 1987-08-23 Центральный институт усовершенствования врачей Method of obtaining artificial osseous transplants
DE3433210C1 (en) * 1984-09-10 1986-06-05 Hans Dr.med. Dr.med.dent. 8000 München Scheicher Means for filling bone and tooth defects, for bone building, for bone contact layers and for bone and tooth root replacement and use of carbonate apatite for this purpose
US5007930A (en) * 1985-02-19 1991-04-16 The Dow Chemical Company Composites of unsintered calcium phosphates and synthetic biodegradable polymers useful as hard tissue prosthetics
US5034352A (en) * 1985-06-25 1991-07-23 Lifecore Biomedical, Inc. Calcium phosphate materials
JPS62182146A (en) * 1985-10-11 1987-08-10 三井東圧化学株式会社 Hardenable material
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
JPH0645487B2 (en) * 1989-05-19 1994-06-15 徳山曹達株式会社 Curing material
JPH03110999A (en) * 1989-09-25 1991-05-10 Sharp Corp 4-channel stereo emphasis circuit
JPH03174349A (en) * 1989-12-01 1991-07-29 Mitsubishi Materials Corp Hydraulic calcium phosphate cement
US5262166A (en) * 1991-04-17 1993-11-16 Lty Medical Inc Resorbable bioactive phosphate containing cements
JP3000719B2 (en) * 1991-05-28 2000-01-17 三菱マテリアル株式会社 Hydraulic calcium phosphate cement
JP3000718B2 (en) * 1991-05-28 2000-01-17 三菱マテリアル株式会社 Drug sustained release calcium phosphate cement
JPH059383A (en) * 1991-06-29 1993-01-19 Dainippon Ink & Chem Inc Polyarylene sulfide resin composition
JPH0523386A (en) * 1991-07-23 1993-02-02 Mitsubishi Materials Corp Calcium phosphate cement
US5338356A (en) * 1991-10-29 1994-08-16 Mitsubishi Materials Corporation Calcium phosphate granular cement and method for producing same
JPH05319891A (en) * 1992-05-19 1993-12-03 Mitsubishi Materials Corp Globular alpha-type calcium tertiary phosphate and hydraulic calcium phosphate cement composition
JPH0645494A (en) * 1992-07-22 1994-02-18 Nec Corp Package for semiconductor integrated circuit
EP0639366A1 (en) * 1993-08-19 1995-02-22 Kingstar Technology Limited (Uk) Hydroxyapatite cement as bone or tooth replacement
US5336642A (en) * 1993-09-01 1994-08-09 Corning Incorporated Canasite-apatite glass-ceramics
US6201039B1 (en) * 1993-09-21 2001-03-13 The Penn State Research Foundation Bone substitute composition comprising hydroxyapatite and a method of production therefor
US5679294A (en) * 1994-03-02 1997-10-21 Kabushiki Kaisya Advance α-tricalcium phosphate ceramic and production method thereof

Also Published As

Publication number Publication date
US5820632A (en) 1998-10-13
DE68928816D1 (en) 1998-10-22
US5336264A (en) 1994-08-09
EP0347028B1 (en) 1998-09-16
EP0347028A3 (en) 1991-09-11
US4880610A (en) 1989-11-14
JP2863544B2 (en) 1999-03-03
DE68928816T2 (en) 1999-03-18
EP0347028A2 (en) 1989-12-20
JPH0222113A (en) 1990-01-25

Similar Documents

Publication Publication Date Title
CA1332495C (en) In situ calcium phosphate minerals -- method and composition
US5047031A (en) In situ calcium phosphate minerals method
US5129905A (en) Methods for in situ prepared calcium phosphate minerals
US5178845A (en) Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
US5053212A (en) Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
EP0835668B1 (en) Biologically resorbable calcium phosphate cement compositions
US6005162A (en) Methods of repairing bone
US5149368A (en) Resorbable bioactive calcium phosphate cement
US6002065A (en) Kits for preparing calcium phosphate minerals
EP0729365B1 (en) Resorbable bioactive phosphate containing cements
CA2167721A1 (en) Storage stable partially neutralized acid compositions and uses
EP0721320A1 (en) Self-setting calcium phosphate cements and methods for preparing and using them
CA2088169C (en) Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
US20040250729A1 (en) Fast-setting carbonated hydroxyapatite compositions and uses
JP2002509766A (en) Biocement with improved properties

Legal Events

Date Code Title Description
MKEX Expiry